PD-L1 IHC in NSCLC with a global and methodological perspective

The treatment of non-small-cell lung cancer (NSCLC) has undergone a major paradigm shift with the arrival of checkpoint inhibition immunotherapy. While substantial progression has been gained over the past 15 years in the field of oncogenic molecular alterations like EGFR mutations and ALK or ROS1 translocations, only a minority of patients with NSCLC benefit from treatment with oral tyrosine kinase inhibitors (TKI ’s) because of the low prevalence of targetable molecular alterations in adenocarcinoma and almost absence in squamous cell carcinoma of the lung [1].

Source: Lung Cancer - September 18, 2017 Category: Cancer & Oncology Authors: Erik Thunnissen, Adrianus J. de Langen, Egbert F. Smit Tags: Review article Source Type: research